Medigene AG (FRA:MDG1) ROC %: -68.01% (As of Jun. 2024)

What is Medigene AG ROC %?

Medigene AG FRA:MDG1 -10.20% 12 ROC % is -68.01% as of Jun. 2024. GuruFocus rates FRA:MDG1 with a GF Score™ of 12/100.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Medigene AG's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was -68.01%.

As of today (2026-06-28), Medigene AG's WACC % is 0.00%. Medigene AG's ROC % is 0.00% (calculated using TTM income statement data). Medigene AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Medigene AG (FRA:MDG1) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Medigene AG's WACC % is 0.00%. Medigene AG's ROC % is 0.00% (calculated using TTM income statement data). Medigene AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Medigene AG ROC % Related Terms

Medigene AG ROC % Historical Data

* Premium members only.

The historical data trend for Medigene AG's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigene AG ROC % Chart

Medigene AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROC %

Get a 7-Day Free Trial

-29.83

-41.85

-20.62

-24.65

-79.04

Medigene AG Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROC %	Get a 7-Day Free Trial															62.49	-129.29	-59.56	-78.91	-68.01

12GF Score

Medigene AG FRA:MDG1

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Medigene AG ROC % Calculation

Medigene AG's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

	ROC % (A: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2022 )	+	Invested Capital (A: Dec. 2023 ))	/ count )
=	-16.149 * ( 1 - 2.5% )	/	( (20.091	+	19.75)	/ 2 )
=	-15.745275	/	19.9205
=	-79.04 %

where

	Invested Capital		(A: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	51.678	-	1.75	-	( 33.224	-	max(0, 7.415	-	37.252	+	33.224	))
=	20.091

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	31.716	-	1.008	-	( 16.674	-	max(0, 7.179	-	18.137	+	16.674	))
=	19.75

Medigene AG's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-13.28 * ( 1 - 0% )	/	( (19.75	+	19.301)	/ 2 )
=	-13.28	/	19.5255
=	-68.01 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	31.716	-	1.008	-	( 16.674	-	max(0, 7.179	-	18.137	+	16.674	))
=	19.75

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	28.81	-	0.411	-	( 14.024	-	max(0, 6.532	-	15.63	+	14.024	))
=	19.301

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -68.01% mean?

Medigene AG (FRA:MDG1) has a ROC % of -68.01% as of Jun. 2024. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Medigene AG and its competitors.

Is Medigene AG's ROC % too high?

Medigene AG's current ROC % is -68.01%. Overall, Medigene AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Medigene AG's ROC % compare to VRTX and REGN?

Medigene AG's ROC % of -68.01% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Medigene AG and its competitors. Medigene AG's current ROC % is -68.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Medigene AG stock overvalued right now?

Medigene AG (FRA:MDG1) has a current ROC % of -68.01%. The current ROC % is -68.01%. Medigene AG's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Medigene AG (FRA:MDG1), the current ROC % is -68.01% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigene AG Business Description

Industry Healthcare Biotechnology

Comparable Companies VRTX ASX:CSL REGN ALNY XKRX:207940 XBRU:UCB XBRU:ARGX ONC INSM XKRX:068270 BNTX HKSE:01801 HKSE:01177 HKSE:09926 SMMT HKSE:02269 XKRX:196170 INCY RPRX OCSE:GMAB

Address Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

12GF Score

Get the complete analysis for FRA:MDG1

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02

Price

View FRA:MDG1 Analysis

See ROC % data for all stocks →